James Kihara - 25 Mar 2024 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)

Role
PRINCIPAL ACCOUNTING OFFICER
Signature
/s/ Jennifer J. Rhodes, Attorney-in-Fact
Issuer symbol
ACAD
Transactions as of
25 Mar 2024
Net transactions value
$0
Form type
4
Filing time
27 Mar 2024, 20:02:14 UTC
Previous filing
27 Feb 2024
Next filing
09 Apr 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACAD Stock Options (Right to Buy) Award $0 +13,964 $0.000000 13,964 25 Mar 2024 Common Stock 13,964 $17.84 Direct F1
transaction ACAD Restricted Stock Units Award $0 +8,568 $0.000000 8,568 25 Mar 2024 Common Stock 8,568 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the Stock Option will vest and become exercisable on March 25, 2025. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.
F2 Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F3 The restricted stock units vest in four equal annual installments beginning March 25, 2025.